{
    "clinical_study": {
        "@rank": "131084", 
        "arm_group": [
            {
                "arm_group_label": "Raltegravir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Efavirenz", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The current  available antiretroviral (ARV) agents  make possible a successful  treatment of\n       virtually all HIV-infected patients, but some problems related to early mortality are still\n      of concern, mainly in resources-limited settings. There are several published reports\n      showing that such patients are at a significantly higher risk of death during the first\n      months of treatment, in comparison with the observed outcomes in developed countries. One of\n      the consistently detected risks for early mortality across these reports is the baseline low\n      CD4 count, although it does not seem to be the only reason for such outcome. In Brazil and\n      other developing countries, there is still a large proportion of AIDS patients who are\n      diagnosed with AIDS, or only seek health care for HIV infection late in the course of\n      disease. Raltegravir (RAL), the first HIV-1 integrase inhibitor, is a potent and safe ARV\n      drug. The available evidence suggest it promotes a faster decline in HIV-1 plasma viremia,\n      and a higher increase in CD4 cells count, in comparison with those in Efavirenz (EFV) arm.\n      The investigators propose to compare the impact of RAL versus EFV in the early mortality\n      rates for severely ill (CD4+ cells count <50 cells/mm3) patients starting ARV therapy."
        }, 
        "brief_title": "Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients", 
        "condition": "Severely Immunocompromised HIV Patients", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA\n             >1,000 copies/ml)\n\n          -  No previous use of any ARV drug (drug-na\u00efve patients)\n\n          -  Presence of clinical symptoms according to Rio de Janeiro / Caracas\u00b4 AIDS definition\n             (Asthenia, Cachexia/Wasting, Cough, Dermatitis, persistent, Diarrhea, Fever,\n             Lymphadenopathy, Candidiasis, oral, or hairy leukoplasia, Central nervous system\n             dysfunction, Herpes zoster in individual younger than 60 years of age)), and/or any\n             active AIDS-defining condition\n\n          -  Baseline CD4+ cells count equal or lower than 50 cells/mm3\n\n          -  Age equal or higher than 18 years\n\n          -  HIV-1 plasma viral load \u2265 1,000 copies of HIV-1 RNA/ml\n\n        Exclusion Criteria:\n\n          -  Undetectable plasma viral load at screening\n\n          -  CD4 cells count>50 cells/mm3\n\n          -  Asymptomatic individuals"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837277", 
            "org_study_id": "SevereHIV"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltegravir", 
                "intervention_name": "Use of Raltegravir-based regimens", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Efavirenz", 
                "intervention_name": "Efavirenz-based regimens", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Efavirenz"
        }, 
        "lastchanged_date": "April 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "eluz5@yahoo.com.br", 
                    "last_name": "Estela Luz, RN, MSci", 
                    "phone": "32838123"
                }, 
                "facility": {
                    "address": {
                        "city": "Salvador", 
                        "country": "Brazil", 
                        "state": "Bahia", 
                        "zip": "40010-160"
                    }, 
                    "name": "Funda\u00e7\u00e3o Bahiana de Infectologia/SEI"
                }, 
                "investigator": [
                    {
                        "last_name": "Carlos Brites, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fabianna Bahia, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Monica Ponze, RN", 
                    "phone": "5521222739073"
                }, 
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ"
                    }, 
                    "name": "Universidade Federal do Rio de Janeiro"
                }, 
                "investigator": {
                    "last_name": "Mauro Schechter, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Priscila Pelaez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS"
                    }, 
                    "name": "Hospital de Clinicas de Porto Alegre"
                }, 
                "investigator": {
                    "last_name": "Eduardo Sprinz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "eluz5@yahoo.com.br", 
            "last_name": "Estela Luz, RN, MSci", 
            "phone": "557132838123"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "early mortality", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837277"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Funda\u00e7\u00e3o Bahiana de Infectologia", 
            "investigator_full_name": "Carlos Brites", 
            "investigator_title": "Senior Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Viral load", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "CD4 count", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Funda\u00e7\u00e3o Bahiana de Infectologia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Funda\u00e7\u00e3o Bahiana de Infectologia", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Intervention Model: Parallel Assignment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}